IP Journal of Urology, Nephrology and Hepatology Science

---

Mirabegron versus tolterodine for the treatment of overactive bladder: A prospective randomized study

Full Text PDF Share on Facebook Share on Twitter

---

Original Article

Author Details : V. R. Pogula, E. H. Galeti*, S. Davalla

Volume : 4, Issue : 3, Year : 2021

Article Page : 79-83

Suggest article by email

---

Abstract

Objectives: To assess the efficacy of mirabegron and Tolterodine, comparing both drugs by IPSS score at 12th week of intervention.
Materials and Methods: This prospective randomized observational study was conducted in 40 Patients with overactive bladder over 15 months. Patients are divided into two groups, 20 patients (Group-M) receiving Tab Mirabegron 50 mg OD and 20 patients (Group-T) receiving Tab Tolterodine 4 mg OD.
Results: The difference of urine Frequency episodes per 24 hours at the 12th week in Group-M was 2.75 ± 1.41, while that among the Group-T was 1.15 ± 1.04 with a significant p-value < 0>

Conclusion: Mirabegron improved Urgency, the total number of micturition episodes/24 hours, nocturia, IPSS score better than Tolterodine in overactive bladder patients. There is no difference between Mirabegron and Tolterodine in terms of incontinence episodes.

Keywords: Over Active Bladder (OAB); Detrusor Overactivity (DO); International Continence Society(ICS); International Prostate Symptom Score(IPSS)

How to cite : Pogula V R , Galeti E H , Davalla S , Mirabegron versus tolterodine for the treatment of overactive bladder: A prospective randomized study. J Urol Nephrol Hepatol Sci 2021;4(3):79-83

Copyright © 2021 by author(s) and J Urol Nephrol Hepatol Sci. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License (creativecommons.org)